Tissue repair & recovery research
Thymosin Beta-4 (Tβ4): Research, Mechanism & Current Evidence
Naturally occurring 43-amino-acid protein central to cell movement, wound healing and repair research.
Also known as Tβ4 · TB4 · thymosin β4 · RGN-352 (clinical code)
What is Thymosin Beta-4?
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in nearly all human cells and in high concentrations in platelets and wound fluid. It is one of the most abundant proteins involved in cell movement.
It should not be confused with TB-500, which reproduces only a seven-amino-acid section of it.
What is Thymosin Beta-4 researched for?
Chronic wounds including venous stasis and diabetic ulcers, where it reached clinical trials.
Dry eye disease and corneal repair, which also reached clinical trials.
Cardiac repair after heart attack, and neurological injury, both largely preclinical.
- Clinical trials show 67% complete healing versus 25% placebo in pressure ulcers.
- Enhanced tissue regeneration and reduced healing time in surgical wounds.
- Accelerated recovery in muscle, tendon, and ligament injuries.
- Phase 2b trials show 43% reduction in infarct size when given within 6 hours.
- Improved neurological outcomes and functional recovery in animal models.
How does Thymosin Beta-4 work?
Cells move by continuously building and dismantling internal scaffolding made of actin. Thymosin beta-4 binds free actin and holds it in reserve, regulating how quickly that scaffolding can be assembled.
Practically, this influences how fast cells migrate into a wound. Reported downstream effects include new blood vessel formation, reduced inflammation and recruitment of stem cells to injured tissue.
What does the research show?
Unlike TB-500, the full-length protein has genuine clinical trial data: phase 2 studies in chronic wounds and in dry eye disease were completed, with encouraging but not decisive results.
Preclinical cardiac and neurological work is extensive and consistently positive, which is common at that stage.
Limitations of the current evidence
No phase 3 programme has established efficacy in any indication.
Evidence generated with the full-length protein is frequently cited in support of the much shorter TB-500 fragment, which is not a sound substitution.
References
Phase II Dry Eye Clinical Trial
2015
72 subjects showing significant positive effects on ocular discomfort and corneal staining with excellent safety profile.
Controlled clinical trial
Phase I Human Safety Study: Intravenous Thymosin β4
2010
First-in-human study establishing safety and pharmacokinetics in healthy volunteers with no dose-limiting toxicity.
Controlled clinical trial
Cardiac Protection Pilot Study: Thymosin β4 in STEMI Patients
2016
First human study in heart attack patients demonstrating potential clinical benefits in repairing damaged tissue.
Early human study
Neurotrophic Keratopathy Compassionate Use Trial
2010
Complete clearing of persistent corneal defects in most subjects using topical formulation.
Common questions
Why use Thymosin Beta-4 instead of the TB-500 fragment for healing?
Thymosin Beta-4 (full 43 amino acids) provides comprehensive regenerative effects with proven clinical efficacy. TB-500 (7-amino-acid fragment) is more economical and stable. Full-length offers more robust Phase 2 clinical data; fragment offers cost efficiency - both work, choose based on budget and evidence requirements.
Can Thymosin Beta-4 improve cardiac function after a heart attack?
Phase 2b trials showed 43% reduction in heart attack infarct size when Thymosin Beta-4 was administered within 6 hours. It promotes cardiomyocyte migration and survival while stimulating coronary vasculogenesis, indicating potential for cardiac protection, though larger trials are needed for clinical approval.